Belinostat
Back to searchMolecule Structure
Scientific Name
Belinostat
Description of the Drug
Belinostat is a histone deacetylase (HDAC) inhibitor used for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB05015
http://www.drugbank.ca/drugs/DB05015
Brand Name(s)
Beleodaq
Company Owner(s)
Acrotech Biopharma Llc
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Histone deacetylase | PROTEIN FAMILY | INHIBITOR | CHEMBL2093865 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL375656 | |||
| DrugBank | DB05015 | |||
| PubChem: Thomson Pharma | 14899204 | |||
| PubChem | 6918638 | |||
| LINCS | LSM-43181 | |||
| Nikkaji | J2.920.351B | J2.221.253B | ||
| PDBe | 5OG | |||
| BindingDB | 25150 | |||
| EPA CompTox Dashboard | DTXSID60194378 | |||
| Brenda | 75543 | 151865 | 163478 | 39096 |
| ChemicalBook | CB3260643 | CB82628305 | ||
| Guide to Pharmacology | 7496 | |||
| rxnorm | BELINOSTAT | BELEODAQ | ||
| PubChem: Drugs of the Future | 12015640 | |||
| ChEBI | 61076 | |||
| ZINC | ZINC000003818726 |
